What happen to Rgnx

Regenxbio (RGNX) has experienced a significant decline of -17.56% on June 5, 2025. This drop may be attributed to **recent clinical trial updates**. On June 5, 2025, Regenxbio announced new interim data from its Phase 1/2 AFFINITY DUCHENNE trial for RGX-202, a gene therapy for Duchenne muscular dystrophy. Despite the positive results showing continued benefit to patients and a favorable safety profile, the market reacted negatively. This could be due to **higher-than-expected doses** being used in the trial, which may have raised concerns about potential side effects or the therapy's long-term efficacy. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |RGNX|RGNX.O|Regenxbio|20250519|10.1237|185| |RGNX|RGNX.O|Regenxbio|20250520|2.145|185| |RGNX|RGNX.O|Regenxbio|20250521|-3.6|185| |RGNX|RGNX.O|Regenxbio|20250522|2.2822|185| |RGNX|RGNX.O|Regenxbio|20250523|-1.5213|185| |RGNX|RGNX.O|Regenxbio|20250527|-6.5911|185| |RGNX|RGNX.O|Regenxbio|20250528|-5.8434|185| |RGNX|RGNX.O|Regenxbio|20250529|5.0351|185| |RGNX|RGNX.O|Regenxbio|20250530|-1.3378|185| |RGNX|RGNX.O|Regenxbio|20250602|16.9492|185|